Express Pharma

Novartis India’s Biotechnology Leadership Camp held in Hyderabad

9

Three winning students will participate in the International Novartis Biotechnology Leadership Camp to be held at the Novartis Campus in Basel, Switzerland

Mamta Bhatia of Symbiosis Institute of Business Management, Pune; N Krishnan of XLRI, Jamshedpur and Rahul Sheshgiri of MVJ Medical College and Research Hospital, Kempegowda Institute of Medical Sciences, Bengaluru won accolades at the recently concluded Novartis Biotechnology Leadership Camp (BioCamp) that took place recently in Hyderabad. The four-day programme saw participation among 51 students vying to represent India at the International BioCamp being held at the Novartis Campus in Basel, Switzerland from August 28 to 31, 2016.

The inaugural address was delivered by Dr Ashfaq Hasan, Head, Department of Pulmonary Medicine, Owaisi Hospital & Research Centre who spoke on chronic obstructive pulmonary disorder and highlighted the many challenges the disease brings with it. Other speakers included Ganesh Balakrishnan, Partner, Deloitte Touche Tohmatsu India LLP, Prof Deva Priyakumar U, Associate Professor, International Institute of Information Technology and Anu Acharya, CEO mapmygenome.com.

The valedictory address was delivered by Dr AS Soin, Chief Hepatobiliary and Liver Transplant Surgeon & Chairman Institute of Liver Transplantation and Regenerative Medicine, Medanta – Medicity, Gurgaon. His speech on the way transplant has moved by leaps and bounds gave an insight in to the rapidly changing world of medicine driven by technology. Soin also described the advances in medicine and how the students could play a role in furthering the cause of science.

Congratulating the winners, Jawed Zia, Country President, Novartis India said, “India has consistently produced winners at the global BioCamp. Interacting with such a bright group of students is very stimulating. Novartis is reimagining medicine and I look forward to you being a part of this journey.”

EP News BureauMumbai

Comments are closed.